Chronic kidney disease (CKD) is a complex and multifactorial disease, and one of the most
prevalent worldwide. Chronic kidney disease–mineral bone disorders (CKD–MBD) with …

Hyperphosphatemia is a common complication in patients with chronic kidney disease
(CKD), particularly in those requiring renal replacement therapy. The importance of …

A series of problems including osteopathy, abnormal serum data, and vascular calcification
associated with chronic kidney disease (CKD) are now collectively called CKD-mineral bone …

Introduction Hyperphosphatemia is an inevitable complication for patients undergoing
dialysis, as is the resulting need for treatment with phosphate binders. Currently, various …

Phosphate binders in patients with chronic kidney disease - PMC Back to Top Skip to main
content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main …

Background Benefits of phosphate-lowering interventions on clinical outcomes in patients
with CKD are unclear; systematic reviews have predominantly involved patients on dialysis …

Hyperphosphatemia is common in chronic kidney disease (CKD) and is treated by dietary
measures, dialysis techniques and/or phosphate binders. For the present review PubMed …

Despite 10 years of post‐marketing safety monitoring of the phosphate binder lanthanum
carbonate, concerns about aluminium‐like accumulation and toxicity persist. Here, we …

Introduction: Hyperphosphatemia is common in the late stages of chronic kidney disease
(CKD) and is associated with elevated parathormone levels, abnormal bone mineralization …

Progression of chronic kidney disease (CKD) is inevitable. However, the last decade has
witnessed tremendous achievements in this field. Today we are optimistic; the dream of …